On Wednesday, the Food and Drug Administration approved the new drug Taxotere to treat breast cancer patients who do not respond to standard treatment, including chemotherapy. Given intravenously every three weeks, Taxotere has demonstrated in trials that it can shrink tumors. Like Taxol, an drug approved in 1994 to treat breast cancer, Taxotere can cause serious side effects. Taxotere, in the same family as Taxol, can cause additional loss of white blood cells and can affect liver function
Uncategorized
